![Mark Foletta](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mark Foletta
Chairman at
AMN HEALTHCARE SERVICES, INC.
Net worth: 5 M $ as of 2026-05-30
Profile
Mark G.
Foletta currently serves as Chairman at AMN Healthcare Services, Inc. since 2025, Lead Independent Director at DexCom, Inc. since 2015, Independent Director at Enanta Pharmaceuticals, Inc. since 2020, and is a Member of The Financial Executives Institute and Corporate Directors Forum.
Former positions include Independent Director at Anadys Pharmaceuticals, Inc. in 2011, Director at ViaCyte, Inc. from 2013 to 2022, Independent Director at Ambit Biosciences Corp.
in 2014, Independent Director at Regulus Therapeutics, Inc. from 2014 to 2018, Director at Islet Sciences, Inc. in 2013, Chief Financial Officer & Senior VP-Finance at Amylin Pharmaceuticals, Inc. from 2006 to 2012, Audit Manager at Ernst & Young LLP from 1986 to 2000, Chief Financial Officer at Biocept, Inc. from 2015 to 2016, Chief Financial Officer & Executive Vice President at Tocagen, Inc. from 2017 to 2020, Chief Financial Officer, Secretary & Senior VP at Intermark, Inc. from 1986 to 1997, Chief Financial Officer, Secretary & Senior VP at Triton Group Ltd. in 1997, and Principal at Triton Group Management, Inc. from 1997 to 2000.
Education includes undergraduate studies at the University of California, Santa Barbara.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
DEXCOM, INC. 0.02% | 2026-05-27 | 63,183 ( 0.02% ) | 5 M $ | 2026-05-30 |
| 2026-04-30 | 21,598 ( 0.06% ) | 625 694 $ | 2026-05-30 | |
| 2026-03-10 | 0 ( -.--% ) | - $ | 2026-05-30 |
Mark Foletta active positions
| Companies | Position | Start |
|---|---|---|
| AMN HEALTHCARE SERVICES, INC. | Chairman | 2025-02-03 |
| DEXCOM, INC. | Director/Board Member | 2014-11-18 |
| ENANTA PHARMACEUTICALS, INC. | Director/Board Member | 2020-06-28 |
Corporate Directors Forum
 Corporate Directors Forum Miscellaneous Commercial ServicesCommercial Services Operates as corporate directors forum | Corporate Officer/Principal | - |
The Financial Executives Institute | Corporate Officer/Principal | - |
Former positions of Mark Foletta
| Companies | Position | End |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative medicines for people with serious diseases | Director/Board Member | 2022-08-31 |
| FORTE BIOSCIENCES, INC. | Director of Finance/CFO | 2020-06-14 |
| REGULUS THERAPEUTICS INC. | Director/Board Member | 2018-05-30 |
| BIOCEPT, INC. | Director of Finance/CFO | 2016-07-26 |
| ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Mark Foletta
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
82
1st degree connections
18
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 18 |
|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
AMN Healthcare Services, Inc.
 AMN Healthcare Services, Inc. Personnel ServicesCommercial Services Provides healthcare staffing and workforce optimization services | Commercial Services |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures novel small molecule medicines | Health Technology |
Biocept, Inc.
 Biocept, Inc. Medical/Nursing ServicesHealth Services Develops and performs clinical laboratory tests to detection & analysis of tumor cells and cell-free DNA from cerebrospinal fluid | Health Services |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative medicines for people with serious diseases | Health Technology |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Develops and sells molecule kinase inhibitors for the treatment of cancer | Health Technology |
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Develops biopharmaceutical drugs | Health Technology |
Intermark, Inc.
 Intermark, Inc. Miscellaneous Commercial ServicesCommercial Services Provides business services | Commercial Services |
Triton Group Ltd.
 Triton Group Ltd. Auto Parts: OEMProducer Manufacturing Distributes & repairs turbine engines | Producer Manufacturing |
DexCom, Inc.
 DexCom, Inc. Medical SpecialtiesHealth Technology Designs, develops and commercializes continuous glucose monitoring systems for management of diabetes & metabolic health by patients, caregivers and clinicians | Health Technology |
University of California, Santa Barbara
 University of California, Santa Barbara Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enanta Pharmaceuticals, Inc.
 Enanta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small molecule drugs for the treatment of viral infections and liver diseases | Health Technology |
The Financial Executives Institute | |
Corporate Directors Forum
Corporate Directors Forum Miscellaneous Commercial ServicesCommercial Services Operates as corporate directors forum | Commercial Services |
Triton Group Management, Inc. | |
Regulus Therapeutics, Inc.
 Regulus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in discovering and developing of drugs | Health Technology |
Islet Sciences, Inc.
 Islet Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops new medicines and technologies for the diagnosis and treatment of metabolic disease | Commercial Services |
- Stock Market
- Insiders
- Mark Foletta
